Achieving satisfactory bone tissue regeneration in osteoporotic patients with ordinary biomaterials is challenging because of the decreased bone mineral density and aberrant bone microenvironment. In addressing this issue, a biomimetic scaffold (PMEH/SP), incorporating 4‐hexylresorcinol (4HR), and substance P (SP) into the poly(lactic‐go‐glycolic acid) (PLGA) scaffold with magnesium hydroxide (M) and extracellular matrix (E) is introduced, enabling the consecutive release of bioactive agents. 4HR and SP induced the phosphorylation of p38 MAPK and ERK in human umbilical vein endothelial cells (HUVECs), thereby upregulating VEGF expression level. The migration and tube‐forming ability of endothelial cells can be promoted by the scaffold, which accelerates the formation and maturation of the bone. Moreover, 4HR played a crucial role in the inhibition of osteoclastogenesis by interrupting the IκB/NF‐κB signaling pathway and exhibiting SP, thereby enhancing the migration and angiogenesis of HUVECs. Based on such a synergistic effect, osteoporosis can be suppressed, and bone regeneration can be achieved by inhibiting the RANKL pathway in vitro and in vivo, which is a commonly known mechanism of bone physiology. Therefore, the study presents a promising approach for developing a multifunctional regenerative material for sophisticated osteoporotic bone regeneration. A novel biomimetic scaffold incorporating 4‐hexylresorcinol and substance p is prepared for osteoporotic bone regeneration. It controls the sequential release of bioactive agents. This promotes VEGF expressions and enhances cell migration, tube‐formation, and facilitating bone formation. Additionally, it inhibits osteoclastogenesis by interrupting the IκB/NF‐κB signaling pathway. The study demonstrates a promising multifunctional scaffold for sophisticated osteoporotic bone regeneration.